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Objective. The aims of this study were: first, to evaluate the possible effects of a
fructose rich diet (FRD)-induced metabolic syndrome (MS) on different aspects of long
bone histomorphometry in young male rats; second, to investigate the effects of this
diet on bone tissue regeneration; and third, to correlate these morphometric alterations
with changes in the osteogenic/adipogenic potential and expression of specific
transcription factors, of marrow stromal cells (MSC) isolated from rats with fructose-
induced MS.
Materials/Methods. MS was induced in rats by treatment with a FRD for 28 days. Halfway
through treatment, a parietal wound was made and bone healing was evaluated 14 days
later. After treatments, histomorphometric analysis was performed in dissected femoral
and parietal bones. MSC were isolated from the femora of control or fructose-treated rats
and differentiated either to osteoblasts (evaluated by type 1 collagen, Alkaline phosphatase
and extracellular nodule mineralization) or to adipocytes (evaluated by intracellular
triglyceride accumulation). Expression of Runx2 and PPARγ was assessed by Western blot.
Results. Fructose-induced MS induced deleterious effects on femoral metaphysis
microarchitecture and impaired bone regeneration. Fructose treatment decreased the
osteogenic potential of MSC and Runx2 expression. In addition, it increased the adipogenic
commitment of MSC and PPARγ expression.
Conclusions. Fructose-induced MS is associated with deleterious effects on bone
microarchitecture and with a decrease in bone repair. These alterations could be due to a
deviation in the adipogenic/osteogenic commitment of MSC, probably by modulation of the
Runx2/PPARγ ratio.
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1. Introduction
Metabolic Syndrome (MS) is a heterogeneous and multifacto-
rial human disorder associated with increased cardiovascular
risk [1]. Common associated comorbidities observed in MS
patients include insulin resistance, dyslipidemia (particularly
hypertriglyceridemia and low levels of HDL), central obesity,
hypertension, glucose intolerance, diabetesmellitus (DM), and
a high proportion of atherosclerotic disease. MS affects
approximately 25% of adults in Latin America, ranging from
18.8% to 43.3% depending on the country of origin [2]. A similar
prevalence has been observed in the US population, and an
even higher prevalence was reported in certain ethnic groups
around the world [3]. Importantly, the prevalence of MS is
correlated with an increased prevalence of obesity, age, and is
also associated with an increased risk for the development of
DM with its associated cardiovascular complications [4].
Western diets contain substantial amounts of refined
sugars including sucrose, fructose and glucose. Fructose
intake has been associated with higher levels of plasmatic
triglycerides (VLDL) and a decrease in the HDL-cholesterol [5].
According to USDA Nationwide Food Consumption Survey
reports, the average daily fructose intake in the US population
was 37 g in 1978. Sugar-sweetened non-alcoholic beverages,
such as soft drinks, appeared as the major source of fructose,
and adolescents and young adults (19–22 years) of both
genders are the main consumers. Recent data from the
NHANES 1999–2004 study, have estimated an average fructose
intake of 49 g/day, which corresponds to a 30% increase in
daily intake [5]. Several studies performed in rats that received
fructose or sucrose-rich diets reproduced the severe and
adverse metabolic and cardiovascular effects observed in MS
patients [5–8], suggesting that this could be an interesting
animal model to investigate different aspects of MS.
Bone is a highly dynamic tissue [9]. Marrow stromal cells
(MSC) are found in the bone marrow microenvironment and
present the ability to differentiate into various cell types such
as osteoblasts, adipocytes, and chondrocytes [10–12]. In this
context, bone marrow metabolic conditions are determinants
of the biologic balance between osteoblast-mediated bone
formation andmarrow adipogenesis [11]. Diverse factors such
as endogenous hormones and drug treatment can affect this
delicate balance, modifying the osteoblast–adipocyte ratio in
the bone marrow [11]. There is a growing body of clinical
evidence reporting the association of skeletal abnormalities
that include osteopenia, osteoporosis and/or an increased
incidence of low-stress fractures, with MS [13–17] or some of
its individual components such as hypertension [18,19] and
obesity [20], in elderly patients of both sexes. However, this
association has not been found in all studies [21], and its
underlying mechanisms have not been elucidated to date.
The aims of this study were: first, to evaluate the possible
effects of a fructose-rich diet-induced MS on different aspects
of long bone histomorphometry in youngmale rats; second, to
investigate the effects of this diet on bone tissue regeneration;
and third, to correlate these morphometric alterations with
changes in the osteogenic/adipogenic potential and expres-
sion of specific transcription factors, of marrow stromal cells
(MSC) isolated from rats with fructose-induced MS.
2. Methods
2.1. Animal Treatments
Young adultmale Sprague–Dawley rats initiallyweighing 200 to
220 g were used. They were maintained in a temperature-
controlled room at 23 °C with a fixed 12 h light–dark cycle. All
experiments onanimalswere carriedout inconformitywith the
Guidelines on Handling and Training of Laboratory Animals
published by the Universities Federation for Animal Welfare
(1992) [22]. Approval for animal studies was obtained from the
institutional accreditation committee (INIBIOLP’s Animal Wel-
fare Assurance No A5647-01). The animals were divided into
two groups of 6 animals per group: one group received standard
chow and water ad libitum (control, C) and the other group
received standard chow andwater containing 10%w/v fructose
(Biopack, Buenos Aires, Argentina) ad libitum (fructose-rich diet,
FRD) [23]. After 28 days, all animals were sacrificed under
anesthesia by cervical dislocation. This period of time was
chosen because some authors have found that drinking 10%
fructose solution for at least 3 weeks causes, inSprague–Dawley
rats, development of hypertension, hypertriglyceridemia and
impaired glucose tolerance [24,25]. Prior to sacrifice, body
weight was measured and non-fasting blood samples were
obtained for determination of serum biochemical parameters.
Glucose, triglycerides and cholesterol were measured by
commercial kits (Wiener Laboratories, Rosario, Argentina)
with a Metrolab 2300plus automated Chemistry Analyzer
(Metrolab, Argentina). Insulin was determined by a rat-specific
ELISA kit (ALPCO, New Hampshire, USA) and fructosamine was
measuredwithacolorimetric kit (Biosystems, Barcelona, Spain).
2.2. Bone reossification model
The possible effects of a fructose-rich diet-induced MS on the
process of bone repair were evaluated by a reossification
model previously described by Santana et al. [26]. Briefly, half-
halfway through the study (i.e., after 14 days) all animals were
anesthetized by intraperitoneal/intramuscular injection of
0.12 mL/100 g body weight of 62.5 mg/mL ketamine hydro-
chloride and 6.25 mg/mL xylazine (Laboratorios Richmond,
Buenos Aires, Argentina). Circular craniotomy defects of
1.0 mm diameter were performed in the right parietal bones
of animals with a cylindrical low-speed carbide bur. Animals
were then maintained in the previously described conditions
for another 14 days to allow bone lesions to heal partially.
2.3. Histological examination of femoral metaphysis
After sacrifice, both femora of each rat were dissected. One
femur was used for histomorphometric analysis and the other
was used for isolation ofMSC, as described below. The length of
each femurwasmeasured using a Vernier caliper. Femorawere
fixed inNeutral Buffered Formalin (NBF) for 72 h anddecalcified
by consecutive immersions in 10% EDTA (Biopack, Buenos
Aires, Argentina), pH = 7.0. After decalcification, they were
embedded in paraffin, and 5 μm sections were obtained using
an SM 2000R Leica microtome (Leica Microsystems, Wetzlar,
Germany). The sections were stained with Haematoxylin and
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Eosin (H&E), Alcian Blue (AB) or histochemistry for Tartrate
Resistant Acid Phosphatase (TRAP) (Sigma, St. Louis, MO, USA).
H&E staining was used to determine relative trabecular bone
area, definedas the ratio between trabecular boneareaand total
tissue area Tb.Ar/T.Ar [%]; and osteocyte density defined as the
number of osteocytes per squaremillimeter of trabecular bone.
These parameters were determined in the femoral metaphysis.
AB staining was used to evaluate the epiphyseal growth plate
height. The measurements were performed parallel to chon-
drocyte columns in the central two thirds of the proximal
growth plate [27].
TRAP histochemistry was performed to specifically identify
osteoclasts [28]. Osteoclastic density in the primary spongiosa
wasdeterminedas thepositiveTRAPareaper squaremillimeter
of trabecular bone. Photographswere takenwithaMicrometrics
519CU camera system on an Eclipse E400 Nikon microscope
(Nikon, Tokyo, Japan). Images were analyzed using the ImageJ
program (http://www.macbiophotonics.ca/imagej) [29].
2.4. Histological examination of bone reossification
After sacrifice, right parietal bones were dissected and
processed for histologic and quantitative histomorphometric
analysis. Parietal bones were fixed in NBF, decalcified in 10%
EDTA, pH = 7.0, and embedded in paraffin. 5 μmsectionswere
obtained using an SM 2000R Leica microtome. The sections
were stained with Haematoxylin and Eosin (H&E) or histo-
chemistry for Tartrate Resistant Acid Phosphatase (TRAP).
H&E stainingwas used to determine the newly reossified bone
area in the parietal wound, and osteocyte density in the newly
formed bone. Osteoclastic density was calculated as the
positive TRAP area per micrometer of defect perimeter.
Photographs were taken with a Micrometrics 519CU camera
system on an Eclipse E400 Nikon microscope (Nikon, Tokyo,
Japan). Images were analyzed using the ImageJ program
(http://www.macbiophotonics.ca/imagej) [29].
2.5. MSC isolation and incubation
MSC were obtained from the femora of C and FRD rats as
previously described [29]. Briefly, immediately after dissection
bone marrow cells were collected by flushing one femur from
each animal with Dulbecco’s modified essential medium
(DMEM) (Invitrogen, Buenos Aires, Argentina) under sterile
conditions. The resulting suspension was seeded in a 25 cm2
tissue culture flask and incubated in DMEM supplemented
with penicillin (100 UI/mL), streptomycin (100 μg/dL) and 10%
fetal bovine serum (FBS) (Natocor, Córdoba, Argentina) at 37 °C
in a humidified atmosphere with 5% CO2 and 95% air. After
24 h, non-adherent cells were removed by changing culture
medium, after which medium was changed twice a week.
When cells reached confluence (10 to 15 days), the cell
monolayer was detached using 0.12% trypsin–1 mmol/L
EDTA and sub-cultured in tissue plates.
2.6. Cell proliferation Assay
Cell proliferation was determined using the crystal violet
mitogenic bioassay. We have previously shown that the results
of this assay correlate linearly with osteoblast cell number
counted with a haemocytometer [30]. MSC from C and FRD
animals were grown in 24-well plates. After different periods of
culture, cell number was estimated for each condition.
2.7. Osteogenic differentiation of rat MSC
MSC were plated at a density of 5 × 104 cells/well in 24-well
plates containing 10% FBS–DMEM and incubated at 37 °C in a
humidified atmosphere with 5% CO2. After cells reached
confluence, they were induced to differentiate into osteo-
blasts using an osteogenic medium (DMEM containing 10%
FBS, 25 μg/mL ascorbic acid and 5 mmol/L sodium β-glycerol-
phosphate) for a further 15 or 21 days [29]. Medium was
changed twice a week. Prior to, and after 2-3 weeks of
osteogenic induction, the osteoblastic differentiation markers
alkaline phosphatase (ALP), type 1 collagen and extracellular
calcium deposits were determined in cultures of BMPC as
described below.
After 15 days of osteogenic differentiation, cell monolayers
were washed with phosphate-buffered saline (PBS) and lysed
with 200 μL 0.1% Triton-X100. An aliquot of 100 μL of the
lysate was used to evaluate ALP activity by the hydrolysis of p-
nitrophenylphosphate (p-NPP) to p-nitrophenol (p-NP) at
37 °C. The absorbance of p-NP was recorded at 405 nm [30].
Aliquots of the same lysate were used for protein determina-
tion by Bradford’s technique [31]. Type 1 collagen production
was also evaluated after 15 days of culture as reported
previously [32]. Briefly, cell monolayers were fixed with
Bouin’s solution and stained with Sirius red dye for 1 h. The
stained material was dissolved in 1 mL 0.1 N sodium hydrox-
ide, and the absorbance of the solution was recorded at
550 nm. Extracellular calcium deposits (mineralization nod-
ules) were evaluated after 21 days of osteogenic differentia-
tion using alizarin S red staining [33]. Stained calciumdeposits
were extracted with 1 mL 0.1 N sodium hydroxide, recording
the optical density at 548 nm.
2.8. Adipogenic differentiation of rat MSC
To induce adipocyte differentiation, MSC were grown to
confluence in 24-well plates in DMEM supplemented with
10% FBS, after which the cells were cultured for an additional
10 days with DMEM–10% FBS plus 0.5 mmol/L 3-isobutyl-1-
methylxanthine (IBMX), 1 μM dexamethasone (Decadron,
Sidus, Argentina), and 200 nmol/L insulin (Lilly, Buenos
Aires, Argentina). At the end of this adipogenic induction,
cells were lysed with 0.1% Triton-X100 and intracellular
triacylglyceride deposits were analyzed with an enzymatic
commercial kit (Wiener, Rosario, Argentina) according to the
manufacturer’s instructions.Aliquots of the sameextractwere
used for protein determination by Bradford’s technique [31].
2.9. Western Blot Analysis
MSC were grown to confluence in 6-well plates in DMEM–10%
FBS and then differentiated into osteoblasts or adipocytes for
different periods of time as previously described. At the end of
the culture periods, cells were lysed in Laemmli’s buffer [34].
The lysates were heated to 100 °C, and 30 μg of protein was
subjected to 10% SDS-PAGE. The separated proteins were
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transferred to PVDF membranes. After washing and blocking,
the membranes were incubated overnight at 4 °C with an
antibody against Runx2/Cbfa1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) for evaluation of osteoblastogenesis,
and PPARγ (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for evaluation of adipogenesis. In order to normalize the
results, all blots were stripped and reprobed to assess β-
actin (Novus Biologicals, Littleton, CO, USA). Blots were
developed by an enhanced chemiluminescence method.
The intensity of the specific bands was quantified by
densitometry after scanning of the photographic film. Images
were analyzed using the ImageJ program (http://www.
macbiophotonics.ca/imagej).
2.10. Statistical analysis
Results are expressed as the mean ± standard error of the
mean (SEM). Differences between groups were assessed by
Student’s t-test using InStat Graph Pad 3.0 software (Graph
Pad Software, San Diego, CA, USA). Differences were consid-
ered significant when p < 0.05.
3. Results
3.1. Body weight and biochemical evaluation of
experimental groups
There was no significant difference in body weight after the
evaluation period (253.3 ± 10.2 g C vs. 252.0 ± 10.2 g FRD).
Table 1 shows serumprofiles for both experimental groups.
FRD group evidenced non-fasting hyperglycemia (52% higher
than C), hyperinsulinemia (313% higher than C) and hyper-
triglyceridemia (108% higher than C), as well as greater levels
of serum fructosamine (56% higher than C). No significant
difference was observed in cholesterol levels. The parameters
for FRD group are compatible with the development of
fructose-induced MS.
3.2. Histomorphometric analysis shows a deleterious
effect of fructose-induced MS on femoral metaphysis
micro-architecture
There was no significant difference in femoral length between
C and FRD groups (32.5 ± 0.5 mm for C, versus 31.3 ± 0.8 mm
for FRD).
Fig. 1 shows the results obtained from histomorphometric
analysis. No differences between groups were observed for
bone marrow adiposity. H&E staining (Fig. 1, A–F) shows that
there was a significant decrease in osteocyte density in the
FRD group (19% reduction versus C), and while the metaphy-
seal relative trabecular bone area also showed a tendency to
decrease in the FRD group (C: 44% ± 4.8% vs. FRD: 39.0% ±
4.5%) this did not reach statistical significance. The results
obtained from AB staining did not evidence differences in the
height of epiphyseal cartilages between groups (Fig. 1, G–I).
Analysis of TRAP histochemistry shows that FRD rats
had a significantly lower proportion of osteoclast-covered
surface in their femoral primary spongiosa (30% decrease
versus C, Fig. 1, J–L).
3.3. Fructose-induced MS impairs bone regeneration
Fig. 2 shows the quantitative histomorphometric analysis of
tissue sections from parietal wound areas of both experimen-
tal groups. H&E staining showed a significant decrease in
reossification area in the FRD group (40% of C), and that there
were also less osteocytes per area of newly-formed bone
tissue in the FRD group (88% of C) (Fig. 2, C–F). Analysis of TRAP
histochemistry shows that FRD rats had a significantly lower
proportion of osteoclast-covered lesion perimeter (45% of C,
Fig. 2, G–I).
3.4. Fructose-induced MS decreases the osteogenic
potential of MSC
We next evaluated the osteogenic potential of MSC isolated
from the femora of rats from both experimental groups, in
order to explore the possible ex vivo effect of a fructose-rich
diet onMSC. After 28 days, MSCwere obtained fromC and FRD
rats. After the first passage, ALP activity and type 1 collagen
production were determined for all cultures (i.e., prior to
osteogenic differentiation). Cells obtained from FRD rats
showed a significantly lower ALP activity (28% decrease) and
type 1 collagen production (32% decrease) than cells obtained
from C rats (Fig. 3, A, C).
We also evaluated the osteoblastic differentiation of MSC
from both groups after 15 or 21 days of culture in an
osteogenic medium. After 15 days of incubation, MSC derived
from FRD rats expressed lower levels of ALP (37% decrease)
and produced lower amounts of type 1 collagen (25% decrease)
than MSC obtained from C rats (Fig. 3, B, D). Similarly, after
21 days of osteogenic induction, a significant decrease in the
formation of mineralization nodules was observed for MSC
from the FRD group (Fig. 3, E).
Lower measures of osteoblastic markers in FRD-derived
MSC under basal or osteogenic induction could be explained
by poorer proliferation of these cells. To clarify this issue, we
investigated the in vitro proliferative capacity of MSC from
both experimental groups. As can be seen in Table 2, we found
Table 1 – Non-fasting serum profiles after 28 days with or without fructose in drinking water.
Group Glucose [mg/dL] Insulin [ng/mL] Fructosamine [μmol/L] Triglycerides [mg/dL] Cholesterol [mg/dL]
C 164 ± 6 1.26 ± 0.17 147 ± 26 71.5 ± 6.3 47.9 ± 1.7
FRD 250 ± 19 † 5.22 ± 1.35 ‡ 229 ± 20 ‡ 148.4 ± 11.2 ⁎ 49.3 ± 1.1
Results are expressed as the Mean ± SEM, n = 6.
Differences versus C: * p < 0.001, † p < 0.002, ‡ p < 0.05.
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thatMSC obtained from control and FRD animals proliferate at
similar rates, discarding this as a possible cause for our
observed decrease in osteoblastic differentiation of FRD-
derived MSC.
3.5. Fructose-induced MS increases the adipogenic
commitment of MSC
We evaluated the ex vivo effect of a fructose-rich diet on MSC
adipocytic differentiation (by quantitation of triacylglycerides
in cell lysates), prior to and after 10 days of adipogenic
induction (Fig. 4). In their basal state (i.e., before induction)
and after 10 days of adipogenic induction MSC from FRD rats
showed higher levels of triacylglyceride accumulation than
MSC from C rats.
3.6. Fructose-induced MS affects the expression by MSC
of osteoblast- and adipocyte-specific proteins
Wenext evaluated possible changes in the expression of Cbfa1/
Runx2, amarkerof osteoblastogenesis, andofPPARγ to evaluate
adipocytic commitment (Fig. 5). MSC obtained from C and FRD
groups were cultured for different periods of time in basal,
osteogenic or adipogenic media, after which cell lysates were
obtained and submitted to Western immunoblotting as de-
scribed in Methods. Both in their basal (undifferentiated) state
and after 15 days of osteogenic induction, MSC from FRD rats
showed lower levels of the osteoblastic transcription factor
Runx2 (Fig. 5, A)whencomparedwithMSC fromC rats. Analysis
of PPARγ expression in MSC from C rats, showed a significant
increase in the levels of this adipocytic inducer after they were
submitted to 10 days of adipogenic induction. However, MSC
from FRD rats already expressed high levels of PPARγ in their
basal condition, which did not further increase after 10 days of
adipogenic induction (Fig. 5, B). Runx2/PPARγexpression ratio in
basal (undifferentiated) MSC from FRD group was 25-fold lower
than in undifferentiated MSC from C rats.
4. Discussion
The prevalence of obesity and the Metabolic Syndrome (MS)
has been continuously increasing over the past decades.
Additionally, MS can predispose to chronic conditions such
as type 2 Diabetes mellitus and cardiovascular disease [1].
There is also a strong correlation between the continuous
increase in obesity and MS, and an increase in fructose intake
[5]. Although incompletely known, several mechanisms have
been proposed for fructose-induced deleterious effects [35].
For instance, oxidative stress and production of inflammatory
cytokines have been implicated as mediators of fructose and/
or obesity-induced insulin resistance. Recently, several studies
have reported the association of Diabetes and MS with
alterations in bone and mineral metabolism [36,37], although
the effect of Diabetes on bone appears to be consistently
greater than that of MS.
In this study we have evaluated long-bone micro-architec-
ture, bone tissue regeneration and the adipogenic/osteogenic
Fig. 1 – Effects of a Fructose-induced MS on femoral microarchitecture.Representative photographs of histological sections
from the proximal femora of control (A, D, G, and J) and FRD rats (B, E, H, and K), and quantitation of histomorphometric
parameters (C, F, I, and L). Femorawere dissected, processed and stainedwith Haematoxilin & Eosin (A, B, D, and E), Alcian Blue
(G and H) or histochemistry for TRAP (J and K).Differences versus C: * p < 0.0001, # p < 0.05.
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commitment of marrow stromal cells (MSC), in a rat model of
MS induced by a fructose-rich diet (FRD). This widely used
model correlates very well with the human MS phenotype [8],
showing insulin resistance, dyslipidemia, hypertension and
glucose intolerance. In the present study, FRD animals
exhibited post-prandial hyperglycemia with elevated fructo-
samine levels (a marker of non-enzymatic glycosylation),
hypertriglyceridemia and hyperinsulinemia, suggesting overt
insulin resistance.
Our selection of this animal model could help us to further
understand how alterations of insulin metabolism may
induce deleterious effects on bone tissue and functionality.
Considering that the main pathogenic mechanisms of type 2
Diabetes are insulin deficiency and/or insulin resistance, it
could be interesting to evaluate each mechanism separately
by using models of partial insulin deficiency or of insulin
resistance. In this context, we have recently found that
partially insulin-deficient Diabetes in rats induces deleterious
effects on long-bone micro-architecture that are due to a
decrease in MSC osteogenic potential [38].
In the present study, we found that MS induced slight
though significant alterations in bone architecture that were
less evident than those observed in our previous study with
insulin-deficient diabetic rats. Thus, in the FRD group we
found a 20% decrease in the osteocytic density of femoral
trabecular bone and a 30% reduction of osteoclast- covered
(TRAP-positive) bone surface in the primary spongiosa.
However, we were unable to find significant changes in
femoral length, trabecular bone area or growth cartilage
height. Nevertheless, this was a 28-day trial of FRD and a
longer study may reveal additional femoral alterations to
rigorously test the hypothesis of a reduced capacity for bone
maintenance. To our knowledge this is the first report
demonstrating cellular alterations in trabecular bone as a
consequence of a fructose-induced MS. Altogether, our
previous and present results could be indicating that the
degree of micro-architectural alterations of bone leading to
increasingly poorer bone quality could depend on the severity
of the underlying metabolic condition. This is supported by
reports of other authors that the incidence of low-impact bone
fractures in type 1 DM is 7–12 times that of matched non-
diabetic individuals [39,40], but is increased approximately 2-
fold versus controls both in type 2 DM [41] and in MS [13].
Several cross-sectional and longitudinal clinical
studies have reported skeletal abnormalities associated with
MS [13–17] or with some of its individual components such as
hypertension [18,19] and obesity [20], although this associa-
tion has not been found in all studies [21]. On the other hand,
more severe metabolic conditions such as Diabetes could be
associated with an even higher trabecular bone loss and/or
poorer bone quality. In this context, other authors using a
model of streptozotocin-induced type 1 Diabetes, found
significant and progressive trabecular bone loss [42]. With
the more moderate model of partially insulin-deficient
Diabetes induced by streptozotocin–nicotinamide, we only
found a slight decrease in long-bone trabecular area together
Fig. 2 – Effects of a Fructose-induced MS on bone repair of a parietal wound.Representative photographs of histological
sections of a parietal wound performed in control (A, D and G) and FRD rats (B, E and H). A 1 mm circular parietal wound was
performed under anesthesia on day 14 of the in vivo study. After a further 14 days all animals were sacrificed, and the
parietal bones were dissected, processed and stained with Haematoxilin & Eosin (A, B, D, and E) or histochemistry for TRAP
(G andH) to asses newbone formation, osteocyte density, and TRAP positive surface. Quantification of the parameters is shown
in panel C, F and I.
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with an important reduction in osteocyte density, growth
plate height and TRAP activity in the primary spongiosa [38].
Those results were in turn more severe than the bone
alterations we are reporting in our present model of MS,
suggesting that insulin-resistance may affect bone to a lesser
degree than insulin deficiency.
Recent studies show that osteocytes play a crucial, central
role in regulating the dynamic nature of bone in all its
diverse functions. Osteocytes are known to be the principal
sensors for mechanical loading of bone [43]. A reduction in
osteocyte density can be explained by a decrease in osteocyte
formation from active osteoblasts and/or an increase in
osteocyte apoptosis. Both situations could develop as a
consequence of oxidative stress induced by MS, DM or even
Fig. 3 – Effect of fructose-inducedMS onMSC osteogenic potential.MSC obtained from the femora of Control (C) or Fructose-rich
diet (FRD) rats were submitted (or not) to an osteogenic induction, and then evaluated for alkaline phosphatase (ALP) activity,
type 1 collagen secretion and formation of extracellular nodules of mineralization. (A) Basal ALP activity (prior to osteogenic
induction). (B) ALP activity after 15 days of osteogenic induction. (C) Basal type 1 collagen production. (D) Type 1 collagen
production after 15 days of osteogenic induction. (E) Extracellular mineral nodule deposition after 21 days of osteogenic
induction.Differences versus C: * p < 0.05, † p < 0.02, ‡% p < 0.01, § p < 0.001.
Table 2 – Marrow Stromal Cell Proliferation Assay.
Time
[hours]
C [cell number ×
104/well]
FRD [cell number ×
104/well]
0 4.1 ± 0.58 3.9 ± 0.77
24 4.2 ± 0.63 4.2 ± 0.55
48 6.9 ± 0.85 7.9 ± 0.84
96 9.5 ± 0.14 10.2 ± 0.89
MSC from control (C) and FRD animals were plated on 24well plates
(approximately 4 × 104 cells/well). After different incubation
periods, Cell number/well was estimated by the Cristal Violet
assay.
Results are expressed as the Mean ± SEM.
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aging [44]. In rat models, we have found a progressive
reduction in osteocyte density associated both with partial
insulin-deficiency [38] and with insulin resistance (our
present results).
Other authors have been unable to demonstrate changes in
the mechanical properties or mineral density of bone, after a
12-week treatment with a fructose rich diet [45]. We believe
this to be in agreement with the concept that in the short
term, MS induces slight alterations in bonemicro-architecture
but no measurable changes in macroscopic structure. How-
ever, after sufficient time the deleterious microscopic defects
can add up, reducing bone quality enough to increase bone
fracture incidence. This is supported by our current results
showing (1) a decrease in trabecular bone osteocyte density
that could be interpreted as a reduced capacity for bone
maintenance at a micrometric level; and (2) a reduction in
TRAP activity of the primary spongiosa together with no
changes in the height of the epiphyseal growth plate, which in
combination would be expected not to affect bone longitudi-
nal growth at a macroscopic level.
We used a model of bone reossification to evaluate the
effect of fructose-induced MS on bone tissue regeneration. To
this effect, we performed uniformparietal wound as described
previously [29] and allowed them to heal for 14 days. Fructose
treatment was found to simultaneously decrease reossifica-
tion, slightly but significantly reduce osteocytic density and
diminish osteoclastic activity in the lesion site, suggesting a
concerted decrease in bone formation and remodeling. These
alterations in bone healing could be the consequence of
insulin resistance and/or deranged glucose metabolism.
Diabetes has been shown to have negative effects on fracture
healing [46]. In previous experiments we found that strepto-
zotocin-induced Diabetes significantly delayed bone healing
of a parietal defect, with a 75% decrease in bone reossification
area, a 60% decrease in osteocytic density and an increase in
TRAP activity in the reossification area [29]. Thus, both insulin
deficiency and insulin resistance appear to affect bone tissue
regeneration, although different mechanisms could be in-
volved in each case.
Fig. 4 – Effect of fructose-induced MS on MSC adipocytic
differentiation.MSC were obtained from the femora of C and
FRD rats and submitted (or not) to an adipocytic induction,
and then evaluated for intracellular triacylglyceride levels.
Data are mean ± SEM. Differences were:* p < 0.05 C-0d vs
FRD-0d.# p < 0.001 for: C-0d vs C-10d; C-0d vs FRD-10d; FRD-
0d vs C-10d; FRD-0d vs FRD-10d and C-10d vs FRD-10d.
Fig. 5 – Effect of fructose-induced MS on MSC expression of Runx2 and PPARγ.MSC were obtained from the femora of C and
FRD rats and submitted (or not) to an osteogenic or adipogenic induction. Cell lysates were obtained in all cases, and evaluated
by Western blotting to determine expression of (A) the osteoblastic transcription factor Runx2, or (B) the adipogenic protein
PPARγ. Data are express as mean ± SEM.Differences for panel A were:N.S. C-0d vs C-15d; C-0d vs FRD-15d and FRD-0d vs FRD-
15d.* p < 0.05 C-0d vs FRD-0d.† p < 0.01 FRD-0d vs C-15d; C-15d vs FRD-15d.Differences for panel B were:N.S. FRD-0d vs C-10d;
FRD-0d vs FRD-10d and C-10d vs FRD-10d.# p < 0.001 C-0d vs FRD-0d, C-0d vs C-10d and C-0d vs FRD-10d.
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The presence of different factors such as cytokines,
hormones or reactive oxygen species in the bone marrow
microenvironment has the ability to promote the commit-
ment of MSC to different cell types, such as osteoblasts,
adipocytes, and chondrocytes [47]. The present work sought
to evaluate the effect of a fructose-rich diet on the ability of
MSC to differentiate and express specific markers of the
osteoblastic or adipogenic phenotype. Our results show
that fructose-induced MS decreased the ex vivo osteogenic
potential of MSC (Fig. 3) as evaluated by type 1 collagen
production, ALP activity and extracellular matrix
mineralization; and increased the ex vivo adipogenic poten-
tial of MSC (Fig. 4) determined by intracellular triglyceride
accumulation. These findings were associated with a
decrease in Runx2 and an increase in PPARγ expression in
basal (undifferentiated) conditions. Consequently, a reduc-
tion in the Runx2/PPARγ ratio of MSC obtained from animals
with fructose-induced MS was observed (Fig. 5). Furthermore,
when FRD-derived MSC were induced to differentiate to
osteoblasts, Runx2 did not increase to the same degree as it
did in control MSC. Additionally, under adipogenic induction
MSC from control animals increased their levels of PPARγ. On
the other hand, adipogenic induction of FRD-derived MSC did
not further increase their already high levels of PPARγ
expression, although cells became differentiated to adipo-
cytes (Figs. 4 and 5B). These observations could be due to the
possible presence of PPARγ agonists, such as polyunsaturated
fatty acids, in the microenvironment of FRD animals [48]. We
have previously reported a similar pattern using an insulin-
deficient diabetic model [29]. Thus it appears that insulin
resistance or deficiency associated with Diabetes or MS can
modulate the reciprocal regulation of Runx2 and PPARγ in
MSC, promoting their adipogenesis and decreasing their
osteogenic capacity, which in turn could affect bone structure
and function.
In conclusion, we have demonstrated that fructose-
induced MS is associated with deleterious alterations in
bone microarchitecture and in the reossification of bone
lesions. These alterations could be due to a deviation in the
adipogenic/osteogenic commitment of MSC, probably by
modulation of the Runx2/PPARγ ratio.
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